Current Issue : July-September Volume : 2022 Issue Number : 3 Articles : 2 Articles
The COVID-19 pandemic originated in Wuhan, China has caused considerable economic and medical losses worldwide. In the midst of the ongoing Covid-19 outbreak, researchers made tremendous efforts to develop vaccines against the infection. COVID-19 is a challenge with its mass exposure to new agents that may cause vaccines not to be as effective as they have been in relatively small numbers in previous studies. It must be stressed that the effectiveness of vaccines probably outweighs the slight risk of adverse effects, but this does not seem feasible when so many people are exposed. The COVID-19 pandemic can serve as a wakeup call for developing countries to strengthen their pharmacovigilance systems since a trustworthy pharmacovigilance system is vital for safe use of COVID-19 vaccines. In combination with the rapid vaccine development as well as the uncertainty of potential long term adverse events, COVID-19 safety and efficacy studies should be conducted rigorously. Implementing mass vaccinations efficiently requires an ongoing multidimensional active pharmacovigilance strategy. Short term side effects are moderate in frequency, mild in severity and short lived. Adverse effects are more likely to affect young individuals, women and people who have had COVID-19 in the past. However, when so many people around the world are exposed, collecting data from those who believe they have been injured is crucial to their safety. Public health authorities depend primarily on the public to report sensibly and respond to requests for further information....
In India clinical trial has shown more importance within a last couple of years, propelled by economic globalization and hence very favourable economic borough in the country. This prompt growth of clinical trials may be accredited to expansion of clinical trials to India by various pharmaceutical companies. Additionally, the proximity of architecture, corresponding as global treatment, a comprehensive spectrum of prevailing disorders, ethnic dissimilarity, English-speaking health care specialists and medical and information technology, provides proper conditions for conducting clinical trials in the country. However, announce of irregularities in the management of clinical trials has obscure prosper of the industry. These ethical infringements in the industry have reveal escape clause in the regulatory system, which has led to it struggling to supervise clinical trials productively. After subject study is approved regulatory authorities will start looking into speed and approved by the committee, then it is submitted for implementation and providing support in terms of necessary ethics committee for their assessment, infrastructure and investment....
Loading....